F
FibroBiologics
Developing therapies using fibroblasts, which are a type of cell that is found in connective tissue
About FibroBiologics
FibroBiologics is a biotech startup that operates in the medical field, specifically focusing on regenerative medicine. The company's primary focus is on the use of fibroblasts, a type of cell that is abundant in the human body and has the ability to regenerate tissues and organs. This makes them a promising tool for treating a variety of conditions, including autoimmune diseases, degenerative disc disease, and age-related decline in organ function.
Read full description
FibroBiologics' business model revolves around the development and application of fibroblast cell-based therapies. These therapies are being researched as potential treatments for conditions such as multiple sclerosis, degenerative disc disease, and the natural decline of key organs like the thymus and spleen as we age. The company also explores the use of fibroblasts in wound healing, given their natural role in this process.
The company's revenue is likely to come from the sale of these therapies once they have been fully developed and approved for use. The potential market for such therapies is vast, given the wide range of conditions they could potentially treat. The company's clients would primarily be healthcare providers and patients suffering from the conditions their therapies aim to treat.
FibroBiologics is guided by a board of directors and a scientific advisory board composed of industry experts. Their combined experience helps shape the company's strategy and product development, positioning the company for success in the competitive biotech industry.
At a glance
- Status
- Listed
- Founded
- 2021
- Headquarters
- Houston, United States
- Listing
- IPO 2024
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 78.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | May 2026 | $0 | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Apr 2026 | $3M | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for FibroBiologics is 6.8K monthly website visits, down 83.8% over the last three months. FibroBiologics's team grew 6.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
StartEngine
Series B and later2 investors entered at this stage
Global Emerging Markets
Yorkville Advisors
Other known investors1 additional known investor
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about FibroBiologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See FibroBiologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.